In clinical practice, CSF is already used for the amyloid-tau-neurodegeneration (ATN) classification system of AD patients, which assesses levels of amyloid-β (A) and phosphorylated tau (T), along with the evaluation of neurodegeneration (N) by brain imaging, to biologically define AD and distinguish it from other dementias. This evidence concerns the gene MAPT and Alzheimer disease.